Popular on EntSun
- Ohio-based haptic startup Contact CI is launching a new product, "Maestro EP" at CES 2023!
- Mystery Disguise Celebrates 25 years of the Yamaha DJX Keyboard
- WYSIWYG Brings on Board Brandon Fisher as a Business Developer
- Raimi, Astin, 'Mandalorian,' 'Harry Potter' Q&As Among Top Programming at FAN EXPO New Orleans
- 5 Apps to Help You Keep Your New Year's Resolutions
- 5th Annual "Spirit of Our Ancestors Festival" Includes Films Featuring Descendant, Smithsonian Museum Curator as Keynote Speaker, and Updated Play
- Jon Robert Quinn Announces Movie Sequel to High Rise: Path to Nowhere
- IOTech Partners With LATERAL.systems To Deliver AgTech And Industry 4.0 Solutions For Sustainable Food Production
- New Book, "Leading Diversity for Competitive Advantage" Elaborates a Comprehensive, Evidence-based Path to Successful DEI Practice
- Nya Nya Experience 17th Annual Celebrity Fashion & Beauty Expo
Similar on EntSun
- Multi #1 International Best-Selling Author Jennifer S. Wilkov Announces the 2023 April Speak Up Women Conference and Call For Speakers
- Electives, Inc. doubles its live learning library to include more than 450 classes
- STS Capital Partners Announces Sean Friday as New Chief Executive Officer
- AVTECH Software Acquires Long Time United Kingdom Partner OPENXTRA
- 360 Protective Solutions on the Importance of Executive Protection For Executives and VIPs
- Terry Hendricks Honored by DFW Real Producers as Top 1% Realtor
- Jeron Pro-Alertâ„¢ Area of Rescue System is First to Reach UL2525 Listing
- Evins Communications Accelerates Growth with Acquisition of Teuwen Communications
- Astro Dunia Launches Annual Letter 2023: A Financial Astrology Solution for Investors
- Award-Winning, Absurd Workplace Comedy 'Business Inc' showcased at onVIVA.tv
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Bioventus Inc. (BVS) Investors
EntSun News/10972773
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) investors who purchased: (a) Class A common stock pursuant and or traceable to the Offering Documents issued in connection with the Company's February 2021 initial public offering ("IPO"); and/or (b) securities between February 11, 2021 and November 21, 2022, inclusive (the "Class Period"). Bioventus investors have until March 13, 2023 to file a lead plaintiff motion.
If you suffered a loss on your Bioventus investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/bioventus-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.
On or about February 11, 2021, Bioventus conducted its IPO selling 8 million shares of Class A common stock at $13 per share.
On November 16, 2022, Bioventus issued a press release announcing that it could not timely file its quarterly report for the period ended October 1, 2022 because of "the recent decline in the Company's market capitalization subsequent to its previously announced financial results for the third quarter of 2022," which resulted in the Company needing "additional time . . . to assess whether a non-cash impairment charge is required for the third quarter of 2022." The Company also noted that it was "seeking resolution related to the validity of a revised invoice" regarding "rebate claims" which would likely adversely affect the Company's previously announced third quarter 2022 financial results." Moreover, the Company disclosed that "its internal controls related to the timely recognition of quarterly rebates were inadequate."
More on EntSun News
On this news, Bioventus's stock price fell $1.00 per share, or 33.67%, to close at $1.97 per share on November 17, 2022, representing a total decline of 84.85% from the IPO price.
Then, on November 21, 2022, Bioventus issued a press release announcing revised third quarter 2022 results to account for "additional rebate claims related to certain of the Company's products and a non-cash impairment charge" that amounted to $189.2 million "due to the recent decline in […] market capitalization subsequent to [its] previously announced financial results." Additionally, Bioventus advised of various changes to its historical practices that were necessary to account for rebates, stating that these changes materially impacted the Company's evaluation of its ability to meet debt covenants, resulting in liquidity and going concern disclosures.
On this news, Bioventus's stock price fell $0.07, or 3.72%, to close at $1.81 per share on November 22, 2022, thereby injuring investors further.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Bioventus suffered from significant liquidity issues; (2) the Company's rebate practices were unsustainable; (3) accordingly, Defendants overstated the Company's business and financial prospects; (4) Bioventus maintained deficient disclosure controls and procedures and internal control over financial reporting with respect to the timely recognition of quarterly rebates; (5) all the foregoing increased the risk that the Company would be forced to recognize a significant non-cash impairment charge, could not timely file one or more of its financial reports, would have to amend one or more of its financial statements, and could not meet its financial obligations as they came due; and (6) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Follow us for updates on LinkedIn, Twitter, or Facebook.
More on EntSun News
If you purchased or otherwise acquired Bioventus securities during the Class Period, you may move the Court no later than March 13, 2023 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Glancy Prongay & Murray LLP, Los Angeles
Charles H. Linehan, 310-201-9150 or 888-773-9224
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
www.glancylaw.com
shareholders@glancylaw.com
If you suffered a loss on your Bioventus investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/bioventus-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.
On or about February 11, 2021, Bioventus conducted its IPO selling 8 million shares of Class A common stock at $13 per share.
On November 16, 2022, Bioventus issued a press release announcing that it could not timely file its quarterly report for the period ended October 1, 2022 because of "the recent decline in the Company's market capitalization subsequent to its previously announced financial results for the third quarter of 2022," which resulted in the Company needing "additional time . . . to assess whether a non-cash impairment charge is required for the third quarter of 2022." The Company also noted that it was "seeking resolution related to the validity of a revised invoice" regarding "rebate claims" which would likely adversely affect the Company's previously announced third quarter 2022 financial results." Moreover, the Company disclosed that "its internal controls related to the timely recognition of quarterly rebates were inadequate."
More on EntSun News
- Actor Joseph Mason attaches to "Kingsmen"
- Quinn, Raimi, Astin, Ricci, Lloyd Lead Off Celeb Announcements At FAN EXPO Philadelphia, June 2-4
- The Town Of Sun Village California Makes History As The First Black Tribal Township In North America
- OnDemandChina Connects North American Audiences to Top Chinese Content
- Flawless Torres ft. Diamonique x Sean Kingston Releases "Lets Go" on 1/27/23!
On this news, Bioventus's stock price fell $1.00 per share, or 33.67%, to close at $1.97 per share on November 17, 2022, representing a total decline of 84.85% from the IPO price.
Then, on November 21, 2022, Bioventus issued a press release announcing revised third quarter 2022 results to account for "additional rebate claims related to certain of the Company's products and a non-cash impairment charge" that amounted to $189.2 million "due to the recent decline in […] market capitalization subsequent to [its] previously announced financial results." Additionally, Bioventus advised of various changes to its historical practices that were necessary to account for rebates, stating that these changes materially impacted the Company's evaluation of its ability to meet debt covenants, resulting in liquidity and going concern disclosures.
On this news, Bioventus's stock price fell $0.07, or 3.72%, to close at $1.81 per share on November 22, 2022, thereby injuring investors further.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Bioventus suffered from significant liquidity issues; (2) the Company's rebate practices were unsustainable; (3) accordingly, Defendants overstated the Company's business and financial prospects; (4) Bioventus maintained deficient disclosure controls and procedures and internal control over financial reporting with respect to the timely recognition of quarterly rebates; (5) all the foregoing increased the risk that the Company would be forced to recognize a significant non-cash impairment charge, could not timely file one or more of its financial reports, would have to amend one or more of its financial statements, and could not meet its financial obligations as they came due; and (6) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Follow us for updates on LinkedIn, Twitter, or Facebook.
More on EntSun News
- We're In Paris Is Sidow Sobrino's Newly Released Song and Video
- Abusive Russian to face Pro Wrestling Legend!
- Jim Wilson, Top Notch Realtor in waterfront and beach properties in Redington, Redington Shores, and North Redington Beach, FLorida
- Multi #1 International Best-Selling Author Jennifer S. Wilkov Announces the 2023 April Speak Up Women Conference and Call For Speakers
- Creators Society Animation Podcast Launches Season 3 With An Interview With Kristine Belson, President Of Sony Pictures Animation
If you purchased or otherwise acquired Bioventus securities during the Class Period, you may move the Court no later than March 13, 2023 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Glancy Prongay & Murray LLP, Los Angeles
Charles H. Linehan, 310-201-9150 or 888-773-9224
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
www.glancylaw.com
shareholders@glancylaw.com
Filed Under: Business
0 Comments
Latest on EntSun News
- STS Capital Partners Announces Sean Friday as New Chief Executive Officer
- Skylar Rogers Announces New Album, 'Among the Insanity'
- AVTECH Software Acquires Long Time United Kingdom Partner OPENXTRA
- Underground Radio Station- URS Online
- Melekel translates an inheritance from a distant past in new album titled Ancient Legacy
- Actress Nae Su attaches to upcoming feature films
- Premier Corporate Entertainment Company in Los Angeles Launches Step-By-Step Guide for Wowing Guests
- Nairobi Professional's January Product Spotlight Is "ShapenHold Flat-Iron Hairspray" (NSH10)
- 2 Hot Radio Presents The Southern Outlaws Band LIVE
- "Boca's Best Body" competition Presented by The Berman Team
- ATM Processing Provider DNS Certifies Just.Cash Bitcoin Program
- Celebrate the Lunar New Year in Orlando 2023
- Seasoned Risk Stalwart Brian Hughes Joins Scienaptic As An Investor And Advisor
- Tobu Railway Begins Selling Mobile Version of NIKKO PASS Via Klook
- Dormant Singer-Songwriter Tom Ersin Re-Releases Old Work
- Engine Prelubrication Systems Saves Money on both large and small engines
- Kenny Tiller Releases New Cover Art for Upcoming Audio Drama 'The Atlanta Stories'
- Bjj News: 10 ways to get really good at Brazilian Jiu Jitsu fast
- BIG Records Artist The Southern Outlaws Band are taking on the big stage
- Gold Prospecting is Family Fun